Is Passage Bio Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Passage Bio Inc (PASG) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Passage Bio Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Passage Bio Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Passage Bio Inc?

Muslim investors may consider investing in Passage Bio Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Passage Bio Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Passage Bio Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Passage Bio Inc updated?

The Shariah compliance status of Passage Bio Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Passage Bio Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Passage Bio Inc?

You can check the latest Shariah compliance status of Passage Bio Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

PASG Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 05, 2026

Report Source: 2025 Annual Report

Passage Bio Inc. Stock Analysis PASG

United States Health Care Nano Cap Report: 2025 Annual

Passage Bio, Inc. operates as a genetic medicines company. The company is headquartered in Philadelphia, Pennsylvania and currently employs 24 full-time employees. The company went IPO on 2020-02-28. Its lead clinical product candidate, PBFT02, seeks to elevate progranulin levels to enhance lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus serotype 1, or AAV1, capsid to deliver a functional granulin gene, encoding progranulin (PGRN), to the brain via intra cisterna magna (ICM) administration. Its development programs consist of PBFT02 for the treatment of FTD-GRN, PBFT02 for the treatment of FTD-C9orf72 and amyotrophic lateral sclerosis, and PBFT02 for the treatment of Alzheimer’s disease. Its clinical product candidates include PBGM01, PBKR03 and PBML04. The company also has a preclinical research program that explores multiple potential treatment targets for Huntington's disease.

Key Statistics of Passage Bio Inc (PASG)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$5.06$5.38

Today's Open

$5.21

Volume

42.44K

P/E Ratio (TTM)

52 Week Range

$3.94$20.00

Market Cap

13.70M

Avg. Volume

144.49K

Dividend Yield

Financial Metrics & Statements of Passage Bio Inc (PASG)

FAQ's for Passage Bio Inc (PASG)

According to Musaffa’s Shariah screening methodology, Passage Bio Inc (PASG) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.